| abstract |
The present invention relates to isolated deuterated compounds (e.g., compounds described by Formula (I) and pharmaceutically acceptable salts thereof. The present invention also relates to isotopically enriched compositions that include compounds according to Formula (I) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role, or those conditions in which RIP1 and/or RIP3 protein is a contributing factor, (structure shown) |